FY2019 EPS Estimates for Vanda Pharmaceuticals Inc. Increased by Jefferies Financial Group (VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at Jefferies Financial Group increased their FY2019 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a research report issued to clients and investors on Monday, December 3rd. Jefferies Financial Group analyst C. Howerton now expects that the biopharmaceutical company will earn $1.31 per share for the year, up from their prior estimate of $1.05. Jefferies Financial Group currently has a “Buy” rating and a $40.00 price objective on the stock.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. During the same period last year, the firm posted ($0.03) EPS. Vanda Pharmaceuticals’s revenue for the quarter was up 18.9% on a year-over-year basis.

Several other research analysts also recently issued reports on the stock. Oppenheimer reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday. Stifel Nicolaus set a $36.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday. Cantor Fitzgerald raised shares of Vanda Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $43.00 price objective on the stock in a research report on Tuesday. BidaskClub raised shares of Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 23rd. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $26.00 price objective on the stock in a research report on Saturday, November 17th. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. Vanda Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $33.00.

Shares of Vanda Pharmaceuticals stock opened at $28.94 on Thursday. Vanda Pharmaceuticals has a 1 year low of $13.30 and a 1 year high of $33.44. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -82.69, a price-to-earnings-growth ratio of 3.94 and a beta of 0.87.

Several hedge funds have recently added to or reduced their stakes in VNDA. United Services Automobile Association acquired a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth $211,000. Trexquant Investment LP acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth $212,000. NumerixS Investment Technologies Inc lifted its stake in shares of Vanda Pharmaceuticals by 92.9% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 5,700 shares during the period. Meeder Asset Management Inc. lifted its stake in shares of Vanda Pharmaceuticals by 164.6% in the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 7,102 shares during the period. Finally, Piedmont Investment Advisors Inc. lifted its stake in shares of Vanda Pharmaceuticals by 1,255.3% in the 3rd quarter. Piedmont Investment Advisors Inc. now owns 12,089 shares of the biopharmaceutical company’s stock worth $277,000 after acquiring an additional 11,197 shares during the period. Institutional investors own 99.33% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: How do candlesticks reflect price movement?

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply